DNA Methylation Status of HYAL1 in Malignant and Benign Thyroid Nodules
Horm Metab Res 2023; 55: 869-875 DOI: 10.1055/a-2188-0050Differentiation between benign and malignant thyroid nodules has been a challenge
in clinical practice. Exploring a novel biomarker to determine the malignancy of
thyroid nodules has important implications. We semi-quantitatively determined
the DNA methylation levels of four CpG sites located at the gene body of HYAL1
in formalin-fixed paraffin-embedded (FFPE) tissue samples from 190 early-stage
papillary thyroid cancer (PTC) cases and 190 age- and gender-matched subjects
with benign thyroid nodule (BTN). HYAL1 expression was evaluated by
immunohistochemical (IHC) staining in another cohort of 55 PTC and 55 matched
BTN cases. Covariates-adjusted odds ratios (ORs) for 10% increased
methylation were calculated by binary logistic regression. A 165 bp
amplicon covering four CpG sites at the second exon of HYAL1 gene was designed.
After adjusted for all covariates, higher methylation level of HYAL1_CpG_3,4 in
the FFPE tissue was associated with PTC (OR per 10% increased
methylation=1.53, p=0.025), even with stage І PTC (OR
per 10% increased methylation=1.58, p=0.021).
Hypermethylation of HYAL1_CpG_3,4 had a significant association with early-stage
PTC in the females (OR per 10% increased methylation=1.60,
p=0.028) rather than in the males. Besides, we fou...
Source: Hormone and Metabolic Research - Category: Endocrinology Authors: Li, Mengxia Yin, Yifei Zhang, Minmin Jiang, Chenxia Li, Hong Yang, Rongxi Tags: Original Article: Endocrine Research Source Type: research
More News: Cancer | Cancer & Oncology | Endocrinology | Genetics | Hormones | Men | Study | Thyroid | Thyroid Cancer